▶ CEREBROLYSIN · SUBTOPIC · SAFETY PROFILE
CEREBROLYSIN Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of CEREBROLYSIN.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of CEREBROLYSIN. Severity, frequency, and attribution depend on the source publication.
- Injection-site reactions
- Mild headache
- Vertigo
- Rare hypersensitivity reactions
- Mild elevations in body temperature reported
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for CEREBROLYSIN.
- No major drug-drug interactions documented
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for CEREBROLYSIN in the published record:
- Severe renal impairment
- Status epilepticus (theoretical lowering of seizure threshold)
- Pregnancy/lactation (limited data)
- Hypersensitivity
FDA REGULATORY STATUS
Not FDA-approved. Marketed by EVER Neuro Pharma in 50+ countries (Europe, Asia, Latin America) for stroke recovery, TBI, and vascular dementia. Research-use only in the United States.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026).
SAFETY Q+A FROM LITERATURE
▶ Is Cerebrolysin FDA-approved?
No. Cerebrolysin is approved in Europe, Asia, and Latin America (50+ countries) but has not been approved by the FDA. Research-use only in the United States.
▶ Is Cerebrolysin WADA-prohibited?
Cerebrolysin is not currently listed on the WADA Prohibited List as of 2026.
▶ Is Cerebrolysin safe?
Published safety data across decades of European clinical use describes generally good tolerability with mild injection-site reactions, headache, and rare hypersensitivity reactions as the most common adverse events. Severe renal impairment and status epilepticus are contraindications.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Muresanu DF, Heiss WD, Hoemberg V, et al.. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke 2016. PMID 26786114. link
- Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci 2018. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25